Please login to the form below

Not currently logged in
Email:
Password:

Medgenics confirms appointment of Dr Marvin Garovoy

Chief medical officer brings experience from companies including Genentech and Xoma

US and Israel-based medical technology and therapeutics company Medgenics has appointed Dr Marvin Garovoy as chief medical officer.

A transplant nephrologist by training, Dr Garovoy has 16 years' experience in the biotechnology and pharmaceutical industries and first joined Medgenics as acting chief medical officer in January.

His industry experience includes stints at Genentech, Xoma Corporation, and Hyperion Therapeutics, while his medical careers has also seen him serve as professor of surgery, medicine and laboratory medicine at the University of California, San Francisco as well as an assistant professor of medicine at Harvard Medical School.

Andrew Pearlman president and CEO of Medgenics, said: “Dr Garovoy's vast experience and skillset will be a considerable asset as we initiate several new clinical trials through to the end of 2012 in the US and Israel, and leverage our Biopump platform technology as we explore the expansion of our development portfolio into new indications.”

The company's Biopump uses a patient's own tissue to continuously produce and deliver their protein therapy and, potentially, has applications in a range of chronic diseases, including diabetes, multiple sclerosis and arthritis.

Dr Garovoy said: “The Biopump technology holds promise to improve the healthcare of millions of people and could be truly transformative for patients, their physicians and payers. I am excited to be a part of the Medgenics team and look forward to working toward bringing these treatments to market.”

16th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill Healthcare Communication

infill is an innovative, European healthcare agency with >20 years' experience in delivering healthcare communication, medical education and digital strategy...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...